US Patent

US10654827 — Therapeutic compounds

Method of Use · Assigned to Gilead Sciences Inc · Expires 2037-08-17 · 11y remaining

Vulnerability score 53/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a compound formula useful in treating a Retroviridae viral infection, including an HIV virus infection.

USPTO Abstract

The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.

Drugs covered by this patent

lenacapavir-sodium (LENACAPAVIR SODIUM)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3507`	—	lenacapavir-sodium
`U-3507`	—	lenacapavir-sodium

Patent Metadata

Patent number: US10654827
Jurisdiction: US
Classification: Method of Use
Expires: 2037-08-17
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Sciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.